Compass says depression drug has long-lasting benefits
Compass Pathways' psilocybin depression therapy shows six‑month durability, sparking market optimism.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Compass Pathways reported six‑month results from its second Phase 3 trial of the psilocybin‑based compound COMP006, indicating a rapid and durable effect in treating depression. Coverage highlights the positive data, noting share price gains and the company’s plan to seek a launch in the first half of 2027.
Business Wire, Moomoo, Psychedelic Alpha, Endpoints News and STAT all reported on the trial outcomes and the upcoming year‑end filing. Next steps include the anticipated year‑end regulatory filing and a potential H1 2027 market launch, according to the statements in the reports.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 129d ago.
Quick answers
What trial phase and duration were disclosed?
Compass Pathways released six‑month data from its second Phase 3 trial of the psilocybin drug COMP006.
How did investors respond to the data?
Shares of Compass Pathways rose after the positive late‑stage trial results, as noted by Moomoo.
When does the company aim to launch the treatment?
The firm is targeting a launch in the first half of 2027, per the Psychedelic Alpha report.
Coverage (5)
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 130d ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 130d ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 130d ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 130d ago
- Compass says depression drug has long-lasting benefits STAT · 130d ago
Topics
Related trends
‘Stop obsessing over eight hours’: New study says another sleep goal is just as key
A new study challenges the traditional eight-hour sleep rule by linking irregular sleep schedules directly to mental health conditions.
Scientists Discovered a Mushroom That's Both Toxic and Trippy
Scientists discovered a mushroom in Florida that contains both toxic and psychedelic compounds
Coping with SAD, the seasonal disorder that can bring on months of depression
The end of daylight saving time and shorter winter days can trigger seasonal affective disorder.
'Good' Body Fat Is Linked to Fewer Anxiety And Depression Diagnoses
A widely prescribed blood pressure drug increased calorie-burning brown fat in mice, according to a recent study.
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Usona has filed a New Drug Application for its psilocybin depression treatment, intensifying the competitive race with Compass Pathways for FDA approval.
New clinic in Steamboat Springs offers one-day treatment for depression
A new clinic in Steamboat Springs introduces one-day depression treatments as data emerges on the efficacy of TMS and esketamine for resistant symptoms.